Literature DB >> 20477753

Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors.

Antonio Luchicchi1, Salvatore Lecca, Stefano Carta, Giuliano Pillolla, Anna L Muntoni, Sevil Yasar, Steven R Goldberg, Marco Pistis.   

Abstract

The endocannabinoid system regulates neurotransmission in brain regions relevant to neurobiological and behavioral actions of addicting drugs. We recently demonstrated that inhibition by URB597 of fatty acid amide hydrolase (FAAH), the main enzyme that degrades the endogenous cannabinoid N-acylethanolamine (NAE) anandamide and the endogenous non-cannabinoid NAEs oleoylethanolamide and palmitoylethanolamide, blocks nicotine-induced excitation of ventral tegmental area (VTA) dopamine (DA) neurons and DA release in the shell of the nucleus accumbens (ShNAc), as well as nicotine-induced drug self-administration, conditioned place preference and relapse in rats. Here, we studied whether effects of FAAH inhibition on nicotine-induced changes in activity of VTA DA neurons were specific for nicotine or extended to two drugs of abuse acting through different mechanisms, cocaine and morphine. We also evaluated whether FAAH inhibition affects nicotine-, cocaine- or morphine-induced actions in the ShNAc. Experiments involved single-unit electrophysiological recordings from DA neurons in the VTA and medium spiny neurons in the ShNAc in anesthetized rats. We found that URB597 blocked effects of nicotine and cocaine in the ShNAc through activation of both surface cannabinoid CB1-receptors and alpha-type peroxisome proliferator-activated nuclear receptor. URB597 did not alter the effects of either cocaine or morphine on VTA DA neurons. These results show that the blockade of nicotine-induced excitation of VTA DA neurons, which we previously described, is selective for nicotine and indicate novel mechanisms recruited to regulate the effects of addicting drugs within the ShNAc of the brain reward system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20477753      PMCID: PMC3167063          DOI: 10.1111/j.1369-1600.2010.00222.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  51 in total

1.  Endocannabinoid signaling mediates cocaine-induced inhibitory synaptic plasticity in midbrain dopamine neurons.

Authors:  Bin Pan; Cecilia J Hillard; Qing-song Liu
Journal:  J Neurosci       Date:  2008-02-06       Impact factor: 6.167

Review 2.  Endocannabinoid-mediated control of synaptic transmission.

Authors:  Masanobu Kano; Takako Ohno-Shosaku; Yuki Hashimotodani; Motokazu Uchigashima; Masahiko Watanabe
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

3.  The endogenous cannabinoid system modulates nicotine reward and dependence.

Authors:  Lisa L Merritt; B R Martin; C Walters; A H Lichtman; M Imad Damaj
Journal:  J Pharmacol Exp Ther       Date:  2008-05-01       Impact factor: 4.030

4.  Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

Authors:  Zuzana Justinova; Regina A Mangieri; Marco Bortolato; Svetlana I Chefer; Alexey G Mukhin; Jason R Clapper; Alvin R King; Godfrey H Redhi; Sevil Yasar; Daniele Piomelli; Steven R Goldberg
Journal:  Biol Psychiatry       Date:  2008-09-23       Impact factor: 13.382

Review 5.  Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis.

Authors:  William A Carlezon; Mark J Thomas
Journal:  Neuropharmacology       Date:  2008-07-15       Impact factor: 5.250

6.  Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors.

Authors:  Miriam Melis; Giuliano Pillolla; Antonio Luchicchi; Anna Lisa Muntoni; Sevil Yasar; Steven R Goldberg; Marco Pistis
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

Review 7.  The role of CB1 receptors in psychostimulant addiction.

Authors:  Joost Wiskerke; Tommy Pattij; Anton N M Schoffelmeer; Taco J De Vries
Journal:  Addict Biol       Date:  2008-06       Impact factor: 4.280

8.  A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions.

Authors:  Laura Orio; Scott Edwards; Olivier George; Loren H Parsons; George F Koob
Journal:  J Neurosci       Date:  2009-04-15       Impact factor: 6.167

9.  Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats.

Authors:  Maria Scherma; Leigh V Panlilio; Paola Fadda; Liana Fattore; Islam Gamaleddin; Bernard Le Foll; Zuzana Justinová; Eva Mikics; Jozsef Haller; Julie Medalie; Jessica Stroik; Chanel Barnes; Sevil Yasar; Gianluigi Tanda; Daniele Piomelli; Walter Fratta; Steven R Goldberg
Journal:  J Pharmacol Exp Ther       Date:  2008-08-25       Impact factor: 4.030

Review 10.  Endocannabinoid system involvement in brain reward processes related to drug abuse.

Authors:  Marcello Solinas; Sevil Yasar; Steven R Goldberg
Journal:  Pharmacol Res       Date:  2007-09-08       Impact factor: 7.658

View more
  38 in total

1.  Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse.

Authors:  Salvatore Lecca; Miriam Melis; Antonio Luchicchi; Anna Lisa Muntoni; Marco Pistis
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

Review 2.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

3.  The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats.

Authors:  Colin N Haile; Therese A Kosten
Journal:  Neuropharmacology       Date:  2017-01-11       Impact factor: 5.250

4.  Inhibition of monoacylglycerol lipase reduces nicotine reward in the conditioned place preference test in male mice.

Authors:  Pretal P Muldoon; Lois S Akinola; Joel E Schlosburg; Aron H Lichtman; Laura J Sim-Selley; Anu Mahadevan; Benjamin F Cravatt; M Imad Damaj
Journal:  Neuropharmacology       Date:  2020-05-30       Impact factor: 5.250

Review 5.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

6.  Fatty acid amide hydrolase (FAAH) inactivation confers enhanced sensitivity to nicotine-induced dopamine release in the mouse nucleus accumbens.

Authors:  Francisco J Pavon; Antonia Serrano; Nimish Sidhpura; Ilham Polis; David Stouffer; Fernando Rodriguez de Fonseca; Benjamin F Cravatt; Rémi Martin-Fardon; Loren H Parsons
Journal:  Addict Biol       Date:  2017-06-29       Impact factor: 4.280

Review 7.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

8.  Role of the satiety factor oleoylethanolamide in alcoholism.

Authors:  Ainhoa Bilbao; Antonia Serrano; Andrea Cippitelli; Francisco J Pavón; Andrea Giuffrida; Juan Suárez; Nuria García-Marchena; Elena Baixeras; Raquel Gómez de Heras; Laura Orio; Francisco Alén; Roberto Ciccocioppo; Benjamin F Cravatt; Loren H Parsons; Daniele Piomelli; Fernando Rodríguez de Fonseca
Journal:  Addict Biol       Date:  2015-06-02       Impact factor: 4.280

9.  The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice.

Authors:  Bogna M Ignatowska-Jankowska; Pretal P Muldoon; Aron H Lichtman; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2013-05-08       Impact factor: 4.530

Review 10.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.